NewVac

213 views

Published on

26-28 MAY, 2013 - FIRST ANNUAL YOUTH ENTREPRENEURSHIP AND INNOVATORS CONFERENCE IN RUSSIA. STARTUP VILLAGE - one of the most ambitious start-up conferences in Russia, organized by Skolkovo in cooperation with partners. The conference is the first this year and will be held annually.

NewVac is the first conference day's pitch session participant in the Life Science pavillion.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
213
On SlideShare
0
From Embeds
0
Number of Embeds
29
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

NewVac

  1. 1. More than 8 million death cases per yearAccording to WHO USA, Western Europe, India, China and Russia arethe countries with the highest incidence of cancerWorld market of the anticancer medicine exceeded $50 billion in2010, including $1 billion of the Russian marketCAGR of anticancer drugs market is 12-15%CANCER – PROBLEM WE SOLVE
  2. 2. WHAT WE DOPersonalized medicineDevelopment and commercialization of cell based vaccine therapy anddiagnosticsDevelopment of new standards of treatmentCombinational cancer therapyAdjuvants+ vaccinesTargeted therapy+ vaccinesTargeted therapy+ radio- and chemotherapyGMP manufacturingPersonalized vaccines, cell therapy and diagnostics
  3. 3. OUR CANCER DRUG PIPELINEOncophageadjuvant therapy for renal cell carcinomaOncophageadjuvant therapy for ovarian cancerOncophage + Votrientmetastatic renal cell carcinomaQuisinostat + SOCnon-small cell lung cancer, ovarian cancerDendritic cell vaccine + А2Аdisseminated melanomaА2А:newantagonistsPre-clinical Phase I Phase II Phase III Market
  4. 4. UNIQUE GMP FACILITY FORPERSONALIZED VACCINESProduction of a wide range of personalizedvaccine for anticancer therapy(protein, dendritic cell-based etc.) andinjection forms for the treatment and clinicalresearch• 09’2012 – 11’2012 staff training on AgenusGMP manufacture in Boston, USA• 12’2012 –02’2013 development ofmanufacturing regulations and the acceptanceof quality assurance system• 03’2013 – licensing of the production in theMinistry of industry and trade• 06’2013 - start of the contract manufacturing ofvaccines for clinical trials (3 preliminaryagreements)• 11’2013 – manufacturing of the first product forthe patient treatment
  5. 5. OUR TEAMIgorOrshanskiy, CEOPhD, 8 years ofbiotech andpharma projectmanagementSergeyDudkin, Strategy directorMD, 15-yearsmarketingexperience atBigPharmacompaniesAndreyGolubev, Medical directorMD, 11-yearsmedical advisorexperience atBigPharmacompaniesIlyaKazeev, Manufacturing directorPhD, 11-yearsexperience inmanufacturingat biotechcompanies
  6. 6. WHAT WE SEEK• Clinical trials, registration and promotion of newproductsINVESTORS FOR• Pipeline extension• Collaboration in drug localization and market accessPARTNERS FOR• Contract manufacturing of innovative vaccines andcell productsCLIENTS FOR
  7. 7. COMPANY OF A NEW TYPEThe specializedresearch-and-productionpharmaceutical companyfor development andcommercialization ofpersonalized medicinemethods forprophylaxis, diagnosticsand treatment of cancer.

×